AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02573142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyles Clinic
Description: Clinic-only model of care including clinical care and educational materials
Study NCT04506073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: 1 dose is 10 X 10\^6 MSC/kg
Study NCT04506073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
Study NCT04506073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigational product but will not contain mesenchymal stem cells (MSCs).
Study NCT00352027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin®
Description: Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
Study NCT00352027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
Study NCT00352027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrogen Mustard
Description: Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
Study NCT00352027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
Study NCT00352027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Study NCT00352027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
Study NCT03789929 — intervention group
Intervention type: BEHAVIORAL
Intervention: The Emotional Backpack
Description: In this 4 weeks course participants learn how to process difficult emotions that has been overwhelming in the past. They learn how they can use the support of other people and support other people in the processing emotions within a simple and easy to learn setting.
Study NCT03789929 — intervention group
Intervention type: BEHAVIORAL
Intervention: Feelings as Powers
Description: In this 3 months course participants learn about the empowering potential of their feelings as well as the difficult aspects of them. In addition to that they learn techniques how to deal with difficult emotions.
Study NCT01930201 — intervention group
Intervention type: PROCEDURE
Intervention: Caudal epidural block
Study NCT01930201 — intervention group
Intervention type: OTHER
Intervention: General anesthesia
Study NCT02686502 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle
Description: As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
Study NCT03306329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets administered once daily
Study NCT00443820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine
Description: Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
Study NCT00443820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle (placebo) once daily for 48 weeks
Study NCT00443820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: terbinafine
Description: Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
Study NCT00443820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle (placebo) once daily for 24 weeks
Study NCT00451906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: As prescribed
Study NCT01829776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
Study NCT03581656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChordArt System
Description: The ChordArt System is intended for chordal replacement in mitral valve insufficiency due to leaflet prolapse or flail. One or more ChordArt System may be utilized within the same intervention for optimal mitral valve treatment.
Study NCT01420289 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High pressure intermittent pneumatic compression (HPIPC)
Description: Apply therapy for 45 minutes twice daily
Study NCT01420289 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Excercise
Description: Treadmill walking 45 minutes once daily
Study NCT00975533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tantalus
Description: The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
Study NCT00975533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
Study NCT00451906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab [Avastin]
Description: 15 mg/kg IV on Day 1 of each 3 week cycle
Study NCT02542202 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo stereotactic body radiation therapy
Study NCT00352027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV on Days 1 and 2 of weeks 1-10.
Study NCT00352027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO every other day of weeks 1-12.
Study NCT01733446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuation of High Frequency Jet Ventilation (HFJV)
Description: In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
Study NCT01478321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT01478321 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: Undergo hypofractionated radiation therapy
Study NCT01478321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01478321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01869296 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: higher flow rates
Description: higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
Study NCT01869296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lower flow rates
Description: lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
Study NCT04702477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness Based Stress Reduction (MBSR) is a well-documented approach to reduce participants' stress level \[19\], with the existing group-based peer support, self-empowerment, and lifestyle counseling intervention. MBSR is a type of meditation therapy with the goal of actively cultivating conscious attention and awareness to enhance health benefits. This included 10 hours of intervention with groups of 3-5 people.
Study NCT03344172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Nab-Paclitaxel, hydroxychloroquine and Avelumab
Description: Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery Day 1 of Cycle 3: avelumab (10mg/kg)
Study NCT03344172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, Nab-Paclitaxel, and hydroxychloroquine
Description: Days 1, 8, 15 of Cycles 1 and 2: gemcitabine (1000mg/m\^2) and nab-paclitaxel (125mg/m\^2) Beginning on Day 8 of Cycle 1: hydroxychloroquine (600mg/BID) daily until day of surgery
Study NCT00450073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol (vitamin D2)
Description: 50,000 IU weekly
Study NCT00450073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sperti Del Sol Lamp
Description: 5 times a week for 12 weeks
Study NCT00450073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 50,000 IU weekly
Study NCT00813891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
Study NCT00813891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
Study NCT00813891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
Study NCT00352027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
Study NCT00352027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
Study NCT00842829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet (FBT)
Description: FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
Study NCT02551419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ketogenic drink
Description: 6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
Study NCT02551419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 6 months' supplementation with the placebo drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
Study NCT01471210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab (BMS-663513)
Study NCT03468582 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 123I radiolabeled 3BNC117
Description: 123I radiolabeled 3BNC117
Study NCT04378231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 200 Mg-28.5 Mg Oral dry suspension
Description: dry suspension of amoxicillin clavulanate potassium
Study NCT02690649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Messaging (Non-Procedural)
Description: Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
Study NCT03802045 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The interventions will be performed by acupuncture specialists with at least 3 years of clinical experience, who will receive prior training to ensure that they rigorously follow the study protocol and are familiar with the types of treatments, including details such as acupuncture points and manipulation of electroacupuncture parameters.~After the randomization, the acupuncturist will sequentially open the envelopes, and the individuals will be randomly assigned to one of five treatment groups: Low frequency EA (LF), high frequency EA (HF), alternating frequency EA (AF), control group (C) and placebo group (P), each containing 25 participants. The acupuncture points will be located and described according to the WHO Standard Acupuncture Locations. Based on the beneficial effects of previous clinical trials, the acupoints selected for this study will be: BL23, BL25, BL40, SP6 and KI3.
Study NCT00842829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Buccal Tablet (FBT)
Description: FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
Study NCT01523184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: This is the placebo capsule
Study NCT01523184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YKP10811 Drug Product Capsule
Description: The drug product, YKP10811, 10 mg under investigation
Study NCT01523184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YKP10811 Drug Product Capsule
Description: The drug product, YKP10811, 20 mg under investigation
Study NCT01523184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YKP10811 Drug Product Capsule
Description: The drug product, YKP10811, 30 mg under investigation
Study NCT02283086 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Feedback Reporting
Description: The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
Study NCT02713594 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counseling from WTQL
Description: Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
Study NCT02713594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling from WTQL
Description: Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
Study NCT02713594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentive to participate
Description: Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
Study NCT03493282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment- CT1812 100 mg
Description: CT1812
Study NCT03493282 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment- CT1812 300 mg
Description: CT1812
Study NCT03493282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT02125409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: One tablet of Adiro 100 mg will be administered daily for 7 days.
Study NCT02125409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Screening colonoscopy
Study NCT01360658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins
Description: Single administration of 2 g/kg intravenous immunoglobulins over 2 days
Study NCT02725047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
Study NCT02725047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sand
Description: Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
Study NCT02888548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: botulinum toxins (Dysport°) alone
Description: botulinum toxins (Dysport°) alone
Study NCT03767309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced flap with abrasive de-epithelized graft.
Description: SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a high-speed hand piece and diamond bur
Study NCT03767309 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap with de-epithelized graft.
Description: SCTG will be harvested from the palate by abrasive de-epithelialization of palatal graft involves removing the epithelium of the selected area with a blade
Study NCT02432924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instant + Multidimensional Physical Activity Feedback
Study NCT04606810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary educational intervention
Description: At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
Study NCT04606810 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: multidisciplinary educational intervention
Description: At randomization, participants in arm 1 received the educational DVD with the instruction to review its contents within the next two weeks. Between 2 and 4 weeks after randomization, reinforcement teleconferences were done in small groups of 10 participants maximum per session with every participant who mentioned having watched the DVD. Each participant attended only to one teleconference. Usual care consisted in regular follow-up with the treating rheumatologist and possibility of asking questions of the rheumatology nurse by phone.
Study NCT04118127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg conventional tablet, once-weekly tablets
Description: In each cohort, subjects will receive a brexpiprazole 2 mg conventional tablet on Day 1of Period 1, the QW formulation on Day 1 of Period 2 and 3, as single and multiple dose in a fasted state.
Study NCT02134340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [I-124]-CPD-1028 Injection
Description: A single intravenous dose of \[I-124\]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
Study NCT02134340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPD-1061
Description: \[Optional\] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of \[I-124\]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.